Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) registered a 0.00% increase, still its new closing price is 10.64% up from the company’s 1 year high of 4.38.It posted 2.46% gains in previous 5 sessions and is now the subject of 0 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 1 buy or better ratings. The 5 stock analysts following this company have an average price target at $6.20, with individual PT in the $4.00-$11.00 range. The shares moved at $2.08, implying that brokerage firms see shares losing about -23.53% in twelve months time.
Rigel Pharmaceuticals, Inc. (RIGL) SEC Form 4 News
The stock is getting much attention these days as insiders are offloading shares while they posted a -12.61% fall year to date. A Chief Medical Officer at Rigel Pharmaceuticals, Inc. (RIGL) offloaded shares in a transaction closed on Tuesday January 03, 2017. Duliege Anne-Marie sold 5,000 shares in the company at $2.41 each and collected $12,000 in proceeds. Duliege Anne-Marie now owns 5,000 shares in the company after this transaction. A EVP, Pres. Discovery&Research in the company, PAYAN DONALD G, disclosed a transaction on Tuesday August 30, 2016 that ended up generating $21,000 from the sale of 5,303 shares at $4 per share.
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Upcoming Results on Tap
Rigel Pharmaceuticals, Inc. will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $-0.17 in that period. Sales during the quarter are predicted to arrive at $2 million.
Rigel Pharmaceuticals, Inc. (RIGL) Brokerage Update
Rigel Pharmaceuticals, Inc. (RIGL) is in JP Morgan’s research list so their analyst rating change is noteworthy. These shares were upgraded to Overweight from Neutral by JP Morgan, according to news reported on Friday April 22, 2016.Another important research note was issued by MP Advisors on Friday December 10, 2010.The firm downgraded RIGL to Market Perform from Outperform. Over the last six months and over the last three months, the shares of Rigel Pharmaceuticals, Inc. (RIGL), have changed -17.13% and -19.69%, respectively.
